A multicenter, double-blind, placebo-controlled parallel study to evaluate the role of Yinhua Miyanling tablets in the prevention of bacterial biofilm formation on ureteral stents: a randomised trial

被引:1
|
作者
Du, Zhen [1 ]
Qiao, Ludong [1 ]
Yang, Weimin [2 ]
Chen, Yuan [2 ]
Zhang, Yong [3 ]
Wu, Wenqi [4 ]
Li, Jun [5 ]
Wang, Wenying [5 ]
Cui, Liang [6 ]
Chen, Shan [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Urol, Beijing, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Urol, Wuhan, Peoples R China
[3] Capital Med Univ, Beijing Tiantan Hosp, Dept Urol, Beijing, Peoples R China
[4] Guangzhou Med Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Peoples R China
[5] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing, Peoples R China
[6] Civil Aviat Gen Hosp, Dept Urol, Beijing, Peoples R China
关键词
Yinhua Miyanling tablet (YMT); ureteral stent; bacterial biofilm; ureteral stent symptom questionnaire; ENCRUSTATION;
D O I
10.21037/apm-22-324
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Yinhua Miyanling tablet (YMT) not only has the functions of clearing away heat and toxin, dredging drenching and diuresis, but also has antibacterial activity. The formation of bacterial biofilm in ureteral stent and its related infection have plagued the clinic. Antibacterial traditional Chinese medicine is a potential method. Methods: This multicenter, randomized, double-blind, placebo-controlled study was designed to enroll patients who underwent ureteroscopic lithotripsy associated with indwelling ureteral stents at six centers between March 2019 and June 2020. The eligible patients were randomly assigned to the experimental group to take YMT 2 g qid orally or the control group to take dummy YMT 2 g qid orally from the first day after the operation according to a random number table. The unused drugs were recalled 14 +/- 3 days after the operation and record the body temperature. Relevant laboratory tests (urinalysis and urine culture) were performed before extubation. The ureteral stent was removed. The specimen was collected for scanning electron microscopy (SEM). Biofilm formation, USSQ scores, postoperative infectious complications, stone formation, and adverse drug reactions were compared between the two groups. Results: Of the 211 patients enrolled, 165 were included in the per-protocol set (PPS), including 86 in the control group and 79 in the experimental group. No significant difference was found between the two groups in baseline parameters (P>0.05). The prevalence of biofilm formation in the control group (47%) was significantly higher than that in the experimental group (22.7%, P=0.001). There was no significant difference in total USSQ score and domain score between the two groups (all P>0.05). There were more patients with symptomatic urinary tract infection (UTI) in the control group (12.9%) than in the experimental group (2.6%, P=0.017). The incidence of other complications did not show a significant difference between the two groups (all P>0.05). The incidence of stone formation on the ureteral stent surface and adverse drug reactions did not show a significant difference between the two groups (all P>0.05). Conclusions: YMT is helpful to reduce the formation of bacterial biofilms on ureteral stents and the incidence of symptomatic UTIs related to ureteral stunting after surgery for ureteral calculi.
引用
收藏
页码:1752 / 1761
页数:10
相关论文
共 50 条
  • [41] Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
    Mullen, Michael
    Jin, Xu Yu
    Child, Anne
    Stuart, A. Graham
    Dodd, Matthew
    Aragon-Martin, Jose Antonio
    Gaze, David
    Kiotsekoglou, Anatoli
    Yuan, Li
    Hu, Jiangting
    Foley, Claire
    Van Dyck, Laura
    Knight, Rosemary
    Clayton, Tim
    Swan, Lorna
    Thomson, John D. R.
    Erdem, Guliz
    Crossman, David
    Flather, Marcus
    LANCET, 2019, 394 (10216): : 2263 - 2270
  • [42] Paracervical anaesthesia in outpatient hysteroscopy: a randomised double-blind placebo-controlled trial
    Lau, WC
    Lo, WK
    Tam, WH
    Yuen, PM
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1999, 106 (04): : 356 - 359
  • [43] Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum
    Nelson-Piercy, C
    Fayers, P
    de Swiet, M
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2001, 108 (01): : 9 - 15
  • [44] Infliximab for the treatment of pyoderma gangrenosum: a randomised, double-blind placebo-controlled trial
    Brooklyn, T
    Shetty, A
    Bowden, J
    Griffiths, C
    Dunnill, G
    Forbes, A
    Greenwood, R
    Probert, C
    GASTROENTEROLOGY, 2005, 128 (04) : A26 - A26
  • [45] Topical dorzolamide for macular holes: A randomised, double-blind, placebo-controlled trial
    Lee, Yong Min
    Bahrami, Bobak
    Baranage, Duleepa
    Sivagurunathan, Premala Devi
    Wong, Wilson
    Bausili, Montserrat Maria
    Agrawal, Surbhi
    Gilhotra, Jagjit Singh
    Durkin, Shane
    Sia, David
    Selva, Dinesh
    Lake, Stewart
    Casson, Robert J.
    Chan, Weng Onn
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 52 (08): : 870 - 879
  • [46] Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial
    Ryan, Nicole M.
    Birring, Surinder S.
    Gibson, Peter G.
    LANCET, 2012, 380 (9853): : 1583 - 1589
  • [47] Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial
    Serpell, MG
    PAIN, 2002, 99 (03) : 557 - 566
  • [48] Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression
    Silvers, KM
    Woolley, CC
    Hamilton, FC
    Watts, PM
    Watson, RA
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2005, 72 (03): : 211 - 218
  • [49] Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial
    Tahan, F.
    Ozcan, A.
    Koc, N.
    EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (01) : 91 - 97
  • [50] Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum
    Whittaker, R
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2003, 110 (01) : 88 - 88